3,809,565 social media conversations analyzed for medication satisfaction, side effect signals, switching patterns, and access barriers.
Data period: February 2023 - February 2026 · 5 social channels · 150+ sources
GLP-1 weight loss medications generated 617,380 relevant online conversations, with weight loss experiences dominating discussion (207,131 mentions) but negative sentiment leading at 254,374 mentions versus 160,975 positive. Experienced patients represent the largest engaged segment at 135,283 mentions, though only 17,710 users express clear satisfaction compared to 21,697 frustrated patients. Nausea emerges as the critical side effect barrier with 20,996 reports - nearly double the next highest concern of muscle loss at 13,024 mentions. High cost drives patient pain points at 47,119 mentions, contributing to 21,875 switching events and 1,433 treatment abandonments across social channels. Dual-agonist medications appear positioned as the primary competitive threat to traditional GLP-1s, with significant switching activity suggesting market disruption ahead.
Gastrointestinal issues dominate negative GLP-1 experiences. Nausea (20,996 reports), GI distress (3,423), and vomiting (8,355) form a tolerability barrier that drives medication switching and discontinuation. Hair loss (4,436 reports) and muscle loss (13,024) are emerging as secondary concerns that patients say their prescribers didn't warn them about.
6.6% of medication switching events result in complete GLP-1 abandonment (1,433 of 21,875 switching events). Consumers are leaving the category entirely - not because the drugs don't work, but because of cost (1,032 mentions), insurance denial (794), and supply shortages (403). The #1 competitor to GLP-1 medications is the healthcare system itself.
Tirzepatide (Mounjaro/Zepbound) shows 71.6% positive sentiment vs semaglutide's 36.6% (n=421,140 and n=96,436 respectively). Conversation volume for tirzepatide is accelerating year over year, and the switching flow data shows a clear directional pattern from semaglutide to tirzepatide products. Caveat: Newer drugs may reflect early-adopter enthusiasm bias. These figures indicate directional trends, not controlled efficacy comparisons.
1,119 consumers mention compounded semaglutide - a cost-driven alternative that bypasses traditional insurance and pharmacy access barriers. With 10,370 off-label usage mentions and 19,611 discontinued patients in the data, the demand for affordable GLP-1 access is creating parallel market channels that pharma companies and insurers cannot ignore.
The satisfaction index reveals a clear split: Ozempic/Wegovy (semaglutide) shows 36.6% positive / 63.4% negative, while Mounjaro/Zepbound (tirzepatide) shows 71.6% positive / 28.4% negative. Supplements and dietary approaches show higher positive rates but lower specificity - consumers report general wellness improvement rather than measurable clinical outcomes.
| Medication | Reported Effect | Count |
|---|---|---|
| ozempic | muscle loss | 2,326 |
| ozempic | nausea | 1,588 |
| semaglutide | muscle loss | 1,473 |
| ozempic | facial aging | 1,374 |
| semaglutide | nausea | 1,242 |
| ozempic | weight regain after stopping | 1,102 |
| ozempic | vomiting | 781 |
| ozempic | ineffective | 767 |
| ozempic | shortage | 707 |
| semaglutide | weight regain after stopping | 676 |
| semaglutide | ineffective | 618 |
| ozempic | gastroparesis | 610 |
| ozempic | hair loss | 574 |
| semaglutide | vomiting | 570 |
| ozempic | facial changes | 550 |
| ozempic | constipation | 468 |
| ozempic | fat loss | 437 |
| glp-1 receptor agonist | muscle loss | 437 |
| ozempic | gastrointestinal issues | 427 |
| ozempic | pancreatitis | 410 |
| From | To | Count | |
|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | → | Tirzepatide (Mounjaro/Zepbound) | 6868 |
| Tirzepatide (Mounjaro/Zepbound) | → | Semaglutide (Ozempic/Wegovy) | 2286 |
| Metformin | → | Semaglutide (Ozempic/Wegovy) | 521 |
| Liraglutide (Saxenda/Victoza) | → | Semaglutide (Ozempic/Wegovy) | 416 |
| Dulaglutide (Trulicity) | → | Semaglutide (Ozempic/Wegovy) | 273 |
| Semaglutide (Ozempic/Wegovy) | → | Dulaglutide (Trulicity) | 201 |
| Tirzepatide (Mounjaro/Zepbound) | → | Retatrutide | 159 |
| Semaglutide (Ozempic/Wegovy) | → | Liraglutide (Saxenda/Victoza) | 153 |
| Semaglutide (Ozempic/Wegovy) | → | Retatrutide | 148 |
| Dulaglutide (Trulicity) | → | Tirzepatide (Mounjaro/Zepbound) | 128 |
| Insulin | → | Semaglutide (Ozempic/Wegovy) | 119 |
| Semaglutide (Ozempic/Wegovy) | → | Metformin | 114 |
| Semaglutide (Ozempic/Wegovy) | → | Insulin | 94 |
| Metformin | → | Tirzepatide (Mounjaro/Zepbound) | 85 |
| Semaglutide (Ozempic/Wegovy) | → | Carnivore Diet | 66 |
Note: Individual switching flow counts are directional indicators, not statistically significant rates. Medication names have been normalized to molecule level - all semaglutide products (Ozempic, Wegovy, Rybelsus) and tirzepatide products (Mounjaro, Zepbound) are consolidated.
1,119 unique consumers discuss compounded semaglutide in the data. This is not a niche phenomenon - it's a market response to access barriers. Consumers seek compounded alternatives primarily because of high cost, insurance denial, and supply shortages of brand-name products. The compounded market represents demand that the traditional pharma channel is failing to serve.
Side effect management is the competitive differentiator. Patients switching from Ozempic/Wegovy to Mounjaro/Zepbound frequently cite better GI tolerability as the reason. The company that solves the nausea-to-discontinuation pipeline - whether through better titration guidance, combination therapies, or next-gen formulations - captures the patients currently abandoning the category. The compounded semaglutide market (1,119 mentions) is a pricing signal, not a fringe phenomenon.
The 6.6% abandonment rate is a cost story. Patients who discontinue GLP-1 therapy often return with worse metabolic outcomes and higher downstream costs. Prior authorization barriers and formulary restrictions that push patients to compounded alternatives or discontinuation may reduce short-term pharmacy spend but increase long-term claims exposure. The switching data suggests that formulary flexibility - not restriction - may be the lower-cost path.
Patients aren't telling you everything in the office. Online, they discuss side effects (hair loss, muscle loss, "Ozempic face") that they may not raise during appointments. They share dosing strategies, discuss compounded alternatives, and compare medications based on peer experiences rather than clinical data. What patients say online is a leading indicator of what they'll ask about next visit - and what might drive non-adherence between visits.
This data shows that GI side effects are the most common experience - but they're also the most commonly managed. Many patients report that side effects diminish after the first few months. The biggest real-world barriers are cost and insurance coverage, not the medications themselves. Ask your provider about titration speed, switching options if one medication doesn't work, and what your insurance actually covers before assuming you can't access treatment.
“Wanted to lose weight, thought about Ozempic, but after the side effects of the bennies I opted for the Leslie Sansome Walk at home program.”
“I have been on Ozempic 13 days and lost 13 pounds. My body rejects grease and as a result I get horrible gas, nausea and diarrhea.”
“My partner used it for a month, lost weight, always taking care of their diet. After using it, they had a complete analysis to see if it altered them in any way, and I would say they are better than before.”
“This type of medication has been used to treat type 2 diabetes and, more recently, in obesity control. They work by reducing appetite, increasing satiety and helping to balance blood glucose.”
“I discontinued zepbound last year because of a prior ed...I was acting like I had in high school when my ed was discovered.”
“I’ve lost 25 pounds and look wonderful and feel wonderful! And showing this woman who didn’t do “all the things” this is just IRRESPONSIBLE.”
“I want to lose 200 pounds and I just don't trust that the drug will keep being available or keep working for that whole journey.”
“The food noise is back and it's definitely harder to maintain than it was to lose.”
“When I was on a GLP my arthritis felt non-existent. It was great. I had to stop due to reflux, and within a week I was back to creaky knees and stiff joints”
“I refused Ozempic and asked for a referral to a nutritionist and a psychologist instead.”
“It works by making you feel so sick you don’t want to eat but some people don’t get that nausea feeling as bad as others and keep their eating habits the same.”
“I lost 50lbs on semaglutide...I completely stopped the medication in May of 2024 and have not gained any weight back...they are literally life changing!”
The patients switching from your drug to a competitor's aren't filling out satisfaction surveys first. They're posting about it online - naming the drug, the side effect, the insurance denial, and the alternative they found instead. The pharma companies and insurers tracking these signals in real time will anticipate market shifts months before they show up in claims data or prescription volumes.
This report is a single snapshot. AskTheFeed delivers continuous monitoring across 150+ social channels - tracking sentiment shifts, emerging safety signals, competitive switching patterns, and compounded market growth, updated in real time. Same data infrastructure, any therapeutic area.
Book a Demo